EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Advancing antihypertensive drug development

Fay Pu, Yanrong Liu, Fozia Zahir Ahmed, Xin Wang iD, Darren Green, Hongyuan Zhang iD

British Journal of Pharmacology · 2025-08 · 182 (15) · 3389-3410

DOI: 10.1111/bph.70063 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2025-06-02. Written by Fay Pu and 5 co-authors. Institution: Intensive care units, University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, UK. Major MEDLINE topics: Antihypertensive Agents, Hypertension, Drug Development. Cited 13 times so far (Crossref); 172 references. The full text is freely available (open access, CC BY 4.0). Funded by: N/A.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Hypertension affects more than a billion individuals worldwide and remains a major cause of cardiovascular morbidity and mortality. Despite advances in therapies, optimal blood pressure control remains elusive for many patients because of treatment resistance, adverse effects, and adherence challenges. This review highlights innovative approaches in hypertension management. Aldosterone synthase inhibitors (ASIs) and non‐steroidal mineralocorticoid receptor antagonists improve blood pressure control and offer cardiorenal benefits while reducing adverse effects including hyperkalaemia. Endothelin receptor antagonists show promise in resistant hypertension by addressing vasoconstrictive pathways. RNA‐based therapies, like zilebesiran, provide a novel approach to suppress angiotensinogen, offering durable antihypertensive effects with less frequent dosing. Additional advances include AT 2 receptor agonists, ACE2/Angiotensin‐(1–7)/MAS receptor activators and NAD + boosting compounds, which target key mechanisms of vascular dysfunction and ageing‐related hypertension. Gut microbiome‐targeted therapies and fixed‐dose combination pills are also discussed for their potential to enhance blood pressure control and patient adherence. These emerging therapies not only aim to lower blood pressure but also address underlying pathophysiological mechanisms, offering a precision‐focussed approach to treatment. By critically analysing these developments, this review provides insights into how novel strategies can overcome existing challenges in hypertension management, reduce the global disease burden and improve patient outcomes.

Subjects

MeSH terms (MEDLINE)

Antihypertensive AgentsHypertensionDrug DevelopmentHumansAnimalsBlood Pressure

Author keywords

endothelin receptor antagonistshypertensionmineralocorticoid receptor antagonist

Substances

Antihypertensive Agents

Authors and institutions

  • Intensive care units, University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, UK.
  • Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Department of Cardiology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Northern Care Alliance NHS Foundation Trust, Salford, UK.

ORCID profiles: Xin Wang, Hongyuan Zhang

Funding

  • N/A

Cite

APA

Pu, F., Liu, Y., Ahmed, F. Z., Wang, X., Green, D., & Zhang, H. (2025). Advancing antihypertensive drug development. British Journal of Pharmacology, 182(15), 3389-3410. https://doi.org/10.1111/bph.70063

Vancouver

Pu F, Liu Y, Ahmed FZ, Wang X, Green D, Zhang H. Advancing antihypertensive drug development. British Journal of Pharmacology. 2025;182(15):3389-3410. doi:10.1111/bph.70063

BibTeX
@article{Pu2025,
  author = {Pu, Fay and Liu, Yanrong and Ahmed, Fozia Zahir and Wang, Xin and Green, Darren and Zhang, Hongyuan},
  title = {Advancing antihypertensive drug development},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {15},
  pages = {3389--3410},
  doi = {10.1111/bph.70063}
}
Start for free →